Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2049)	5/27/2003 9:41:05 AM
From: Biomaven	Respond to of 2243

More strength by GPC in Europe yesterday - bodes well for SPPI: Reuters GPC Bio shares soar on cancer drug hopes Monday May 26, 9:05 am ET FRANKFURT, May 26 (Reuters) - Shares in Germany's GPC Biotech (XETRA:GPCG.DE - News) soared on Monday on hopes that it will report research findings next week that support its key cancer drug satraplatin. ADVERTISEMENT [Ad] GPC Biotech shares were up 10 percent at 5.90 euros at 1239 GMT, while the Tecdax technology index (XETRA:^TECDAX - News) was up 0.24 percent. GPC is due to report data from a 50-patient trial on satraplatin, a pill used to treat prostate cancer that does not respond to hormone therapy, at the annual meeting of the American Society of Clinical Oncology in Chicago. "The rise in the share price is not very surprising... most investors are hoping for good results from satraplatin," said Alexander Burger, an analyst at Landesbank Baden-Wuerttemberg. Satraplatin is the company's most promising product, and GPC has projected peak annual sales of $150 million after an expected launch in 2007. The drug has come through the first two phases of clinical trials and is expected to enter the third phase in the third quarter. It has to clear phase three trials before it can be put on the market.

To: Icebrg who wrote (2049)	5/29/2003 11:41:05 AM
From: Icebrg	Read Replies (2) \| Respond to of 2243

>>>>Spectrum Pharmaceuticals (SPPI)>>>> Time for an update on one of the moon-shot candidates. Spectrum was kind enough to email me a copy of their Annual Report. It is not on the website yet. Not the boring 10K-stuff, but the multicolored version.( From the PDF-file it was not possible to decide where the 10K should be fitted. So I put them side by side in the file archive). OK, there are a couple of things I need to read through and there was one thing I wanted to have confirmed. The report was supposed to include a mini-update on EOquin, their second cancer drug. And yes, there was one. We are currently running a phase 1-2 study of Eoquin™ (formerly Neoquin) in superficial bladder cancer. To date, five patients have been enrolled in the study and three have completed treatment. Each of these three patients have achieved complete remission (or complete disappearance of their tumors). We plan to enroll approximately 25 patients in this study by the end of 2003. Eoquin is a prodrug which is activated by special enzymes present in high amounts in cancer cells. The activated form of Eoquin kills tumor cells with less risk of harming normal body cells. This unique mode of action has led to E o q u i n ’s clinical use in the treatment of superficial bladder cancer. Three out of three is not bad. I wonder what is so special about this type of cancer? I don't know anything about the protocol (yet). I will have to try to find out. One possibility is that these are patients that have had their cancer resected and are treated with EOquin as an adjuvant in order to mop up whatever might have been left behind by the knife. So it is perhaps a little bit to early to call this a break-through. It might just be the work of a very good surgeon. I will continue to keep you informed unless there are howls of protests. (Sometimes I feel almost like a pump-and-dump artist about these very frequent updates . Things are supposed to be very slow-moving in this part of the economy). Erik